{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:15:36Z","timestamp":1780424136199,"version":"3.54.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L006758 \/"],"award-info":[{"award-number":["MR\/L006758 \/"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["ASLAN003"],"award-info":[{"award-number":["ASLAN003"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["BAY2402234"],"award-info":[{"award-number":["BAY2402234"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.tiv.2021.105096","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T01:07:38Z","timestamp":1610932058000},"page":"105096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models"],"prefix":"10.1016","volume":"72","author":[{"given":"Samantha W.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L.","family":"Penman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kevin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tiv.2021.105096_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","article-title":"Hepatotoxicity related to antirheumatic drugs","volume":"7","author":"Aithal","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0010","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.tiv.2021.105096_bb0015","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1158\/0008-5472.CAN-06-3554","article-title":"Mitochondrial genetic background modifies breast cancer risk","volume":"67","author":"Bai","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.10.014","article-title":"Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells","volume":"29","author":"Bajzikova","year":"2019","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/toxsci\/kfw126","article-title":"Identification of the additional mitochondrial liabilities of 2-hydroxyflutamide when compared with its parent compound, flutamide in HepG2 cells","volume":"153","author":"Ball","year":"2016","journal-title":"Toxicol. Sci."},{"issue":"4","key":"10.1016\/j.tiv.2021.105096_bb0030","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1021\/jm0506975","article-title":"Dual binding mode of a novel series of DHODH inhibitors","volume":"49","author":"Baumgartner","year":"2006","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.taap.2006.12.013","article-title":"Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity?","volume":"220","author":"Boelsterli","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20110162","article-title":"Assessing mitochondrial dysfunction in cells","volume":"435","author":"Brand","year":"2011","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0003-9861(85)90660-5","article-title":"The varied responses of different F1-ATPases to chlorpromazine","volume":"236","author":"Bullough","year":"1985","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.tiv.2021.105096_bb0050","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.21536","article-title":"Transdifferentiation of hepatocyte-like cells from the human hepatoma hepaRG cell line through bipotent progenitor","volume":"45","author":"Cerec","year":"2007","journal-title":"Hepatology."},{"issue":"7","key":"10.1016\/j.tiv.2021.105096_bb0055","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.tiv.2021.105096_bb0060","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","article-title":"The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies","volume":"33","author":"Christian","year":"2019","journal-title":"Leukemia."},{"issue":"17\u201318","key":"10.1016\/j.tiv.2021.105096_bb0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.drudis.2007.07.013","article-title":"The significance of mitochondrial toxicity testing in drug development","volume":"12","author":"Dykens","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tiv.2021.105096_bb0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.tiv.2016.03.016","article-title":"A combined in vitro approach to improve the prediction of mitochondrial toxicants","volume":"34","author":"Eakins","year":"2016","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2021.105096_bb0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.redox.2015.07.008","article-title":"Antioxidant responses and cellular adjustments to oxidative stress","volume":"6","author":"Espinosa-Diez","year":"2015","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem. Biol. Interact."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0085","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tiv.2012.11.002","article-title":"A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays","volume":"27","author":"Hynes","year":"2013","journal-title":"Toxicol. in Vitro"},{"issue":"4","key":"10.1016\/j.tiv.2021.105096_bb0090","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.tiv.2015.02.011","article-title":"The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death","volume":"29","author":"Kamalian","year":"2015","journal-title":"Toxicol. in Vitro"},{"issue":"March","key":"10.1016\/j.tiv.2021.105096_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tiv.2018.08.001","article-title":"The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity","volume":"53","author":"Kamalian","year":"2018","journal-title":"Toxicol. in Vitro"},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0100","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.107.017418","article-title":"HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.tiv.2021.105096_bb0105","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.107.020016","article-title":"Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"29","key":"10.1016\/j.tiv.2021.105096_bb0110","doi-asserted-by":"crossref","first-page":"12828","DOI":"10.1073\/pnas.0910885107","article-title":"Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway","volume":"107","author":"Khutornenko","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.tiv.2021.105096_bb0115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2012.04360.x","article-title":"Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?","volume":"75","author":"Kia","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.tiv.2021.105096_bb0120","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0006-2952(98)00145-2","article-title":"Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives","volume":"56","author":"Knecht","year":"1998","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.tiv.2021.105096_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2018.03.005","article-title":"Dependence on the Pyrimidine Biosynthetic enzyme DHODH is a synthetic lethal vulnerability in Mutant KRAS-driven cancers","volume":"25","author":"Koundinya","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.tiv.2021.105096_bb0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(02)01177-4","article-title":"Fatal hepatitis with leflunomide and itraconazole","volume":"113","author":"Legras","year":"2002","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0135","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/toxsci\/kfs100","article-title":"Mitochondrial dysfunction induced by sertraline, an antidepressant agent","volume":"127","author":"Li","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2021.105096_bb0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejmech.2011.12.038","article-title":"New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold","volume":"49","author":"Lolli","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1574892812666171108124218","article-title":"Use of human dihydroorotate dehydrogenase (hDHODH) inhibitors in autoimmune diseases and new perspectives in Cancer therapy","volume":"13","author":"Lolli","year":"2018","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"3","key":"10.1016\/j.tiv.2021.105096_bb0150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/aps.2015.157","article-title":"Inhibition of hepatic cytochrome P450 enzymes and sodium\/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity","volume":"37","author":"Ma","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","article-title":"Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of hepG2 cells to mitochondrial toxicants","volume":"97","author":"Marroquin","year":"2007","journal-title":"Toxicol. Sci."},{"issue":"7","key":"10.1016\/j.tiv.2021.105096_bb0160","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/bi001810q","article-title":"Multiple inhibitor analysis of the Brequinar and Leflunomide binding sites on human dihydroorotate dehydrogenase","volume":"40","author":"McLean","year":"2001","journal-title":"Biochemistry."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00415-009-0075-3","article-title":"Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the dark Agouti rat model of experimental autoimmune encephalomyelitis","volume":"256","author":"Merrill","year":"2009","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.tiv.2021.105096_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2017.12.001","article-title":"Identification of new activators of mitochondrial fusion reveals a link between mitochondrial morphology and pyrimidine metabolism","volume":"25","author":"Miret-Casals","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"SEP","key":"10.1016\/j.tiv.2021.105096_bb0175","first-page":"1","article-title":"Selective cytotoxicity of dihydroorotate dehydrogenase inhibitors to human cancer cells under hypoxia and nutrient-deprived conditions","volume":"9","author":"Miyazaki","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tiv.2021.105096_bb0180","doi-asserted-by":"crossref","first-page":"102129","DOI":"10.1016\/j.msard.2020.102129","article-title":"Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis","volume":"43","author":"Muehler","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.tiv.2021.105096_bb0185","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-014-1665-1","article-title":"Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study","volume":"121","author":"Packer","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.tiv.2021.105096_bb0195","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.tiv.2019.104595","article-title":"Differential toxic effects of bile acid mixtures in isolated mitochondria and physiologically relevant HepaRG cells","volume":"61","author":"Penman","year":"2019","journal-title":"Toxicol. in Vitro"},{"issue":"7","key":"10.1016\/j.tiv.2021.105096_bb0200","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1432-1327.2000.01213.x","article-title":"Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase","volume":"267","author":"Rawls","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"August","key":"10.1016\/j.tiv.2021.105096_bb0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tox.2017.10.002","article-title":"Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 cells","volume":"392","author":"Ren","year":"2017","journal-title":"Toxicology."},{"issue":"6","key":"10.1016\/j.tiv.2021.105096_bb0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","article-title":"Clinical pharmacokinetics of leflunomide","volume":"41","author":"Rozman","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tiv.2021.105096_bb0215","article-title":"Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19","author":"Sales-Medina","year":"2020","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.tiv.2021.105096_bb0220","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/bmc.244","article-title":"Simultaneous determination of leflunomide and its active metabolite, a77 1726, in human plasma by high-performance liquid chromatography","volume":"17","author":"Schmidt","year":"2003","journal-title":"Biomed. Chromatogr."},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/toxsci\/kfv136","article-title":"Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and Detoxication","volume":"147","author":"Sison-Young","year":"2015","journal-title":"Toxicol. Sci."},{"issue":"11","key":"10.1016\/j.tiv.2021.105096_bb0230","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14728222.2018.1536748","article-title":"The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia","volume":"22","author":"Sykes","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.tiv.2021.105096_bb0235","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/db06-1105","article-title":"Women with mitochondrial haplogroup N9a are protected against metabolic syndrome","volume":"56","author":"Tanaka","year":"2007","journal-title":"Diabetes."},{"key":"10.1016\/j.tiv.2021.105096_bb0240","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1289\/ehp.9087213","article-title":"Uncouplers of oxidative phosphorylation","volume":"87","author":"Terada","year":"1990","journal-title":"Environ. Health Perspect."},{"issue":"5","key":"10.1016\/j.tiv.2021.105096_bb0245","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/imt.10.52","article-title":"Leflunomide: a drug with a potential beyond rheumatology","volume":"2","author":"Teschner","year":"2010","journal-title":"Immunotherapy."},{"issue":"4","key":"10.1016\/j.tiv.2021.105096_bb0250","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.tiv.2009.03.008","article-title":"Functional expression, inhibition and induction of CYP enzymes in HepaRG cells","volume":"23","author":"Turpeinen","year":"2009","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2021.105096_bb0255","author":"U.S. FDA"},{"key":"10.1016\/j.tiv.2021.105096_bb0260","author":"U.S. FDA"},{"issue":"34","key":"10.1016\/j.tiv.2021.105096_bb0265","doi-asserted-by":"crossref","first-page":"8929","DOI":"10.1021\/bi8003318","article-title":"The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites","volume":"47","author":"Walse","year":"2008","journal-title":"Biochemistry."},{"issue":"February","key":"10.1016\/j.tiv.2021.105096_bb0270","first-page":"131","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","author":"Weaver","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0275","doi-asserted-by":"crossref","first-page":"C125","DOI":"10.1152\/ajpcell.00247.2006","article-title":"Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells","volume":"292","author":"Wu","year":"2007","journal-title":"Am. J. Physiol. Physiol."},{"key":"10.1016\/j.tiv.2021.105096_bb0280","article-title":"Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2","author":"Xiong","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.tiv.2021.105096_bb0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2018.02.003","article-title":"Mitochondrial dysfunction induced by leflunomide and its active metabolite","volume":"396\u2013397","author":"Xuan","year":"2018","journal-title":"Toxicology"},{"issue":"11","key":"10.1016\/j.tiv.2021.105096_bb0290","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/sj.cdd.4401661","article-title":"Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase","volume":"12","author":"Zamaraeva","year":"2005","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0295","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1189\/jlb.0606378","article-title":"Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-\u03baB in immunological synapse formation","volume":"81","author":"Zeyda","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.tiv.2021.105096_bb0300","article-title":"Multi-omics study revealing tissue-dependent putative mechanisms of SARS-CoV-2 drug targets on viral infections and complex diseases","author":"Zheng","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.tiv.2021.105096_bb0305","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/0008-5472.CAN-11-1674","article-title":"Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells","volume":"72","author":"Zhou","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.tiv.2021.105096_bb0310","article-title":"ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia","author":"Zhou","year":"2019","journal-title":"Haematologica."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233321000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233321000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:41:50Z","timestamp":1778542910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233321000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":62,"alternative-id":["S0887233321000217"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2021.105096","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2021.105096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105096"}}